PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors
2014年1月16日 - 10:30PM
Marketwired
PURE's SDC-Based Food Safety Solutions Strategy Gains Traction --
Initial Orders From Three Food Processors
SAN DIEGO, CA--(Marketwired - Jan 16, 2014) - PURE Bioscience,
Inc. (OTCQB: PURE), creator of the patented silver dihydrogen
citrate (SDC) antimicrobial, today announced continued progress on
its strategic positioning as a food safety solution which was
launched this past Fall.
- PURE Hard Surface, an SDC-based antimicrobial disinfectant for
food contact surfaces, has been proven to show superior efficacy as
a safe, non-toxic product. Following extensive in plant testing of
the product, PURE has received initial orders from three national
food processors. The product continues to be tested at a number of
other leading food processors where initial results have been very
positive.
- In addition, PURE is completing the final stage of testing its
food safety solution in a leading quick service restaurant chain.
Third party validated test results to-date have consistently shown
use of PURE resulting in 90% + greater effectiveness in the
reduction of bacteria and, hence, food safety risk.
- These companies are part of PURE's previously disclosed
customer pipeline of 25 national food companies which represent a
potential annualized revenue stream of $20 - $30 million if fully
rolled out.
"The successful testing and rapid acceptance of PURE as a
superior food safety solution for food processors is an important
step forward in the implementation of our business plan and bodes
well for the additional food processors in our pipeline." said Hank
Lambert, Chief Executive Officer of PURE Bioscience. "Gaining this
initial traction with processors, combined with the prospects we
see for restaurant chains, serves as strong validation for our
strategic positioning of SDC for the food industry."
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and
commercializing its proprietary antimicrobial products that provide
solutions to the health and environmental challenges of pathogen
and hygienic control within the food industry. The Company's
technology platform is based on patented stabilized ionic silver,
and its initial products contain silver dihydrogen citrate, or SDC.
SDC is a broad-spectrum, non-toxic antimicrobial agent, which
offers 24-hour residual protection. As a platform technology, SDC
is distinguished from existing products in the marketplace by its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements inherently involve risks
and uncertainties that could cause our actual results to differ
materially from the forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, the Company's cash position and liquidity requirements,
the Company's failure to implement or otherwise achieve the
benefits of its proposed business initiatives and plans, acceptance
of the Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, including
to manufacture its products, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission, including our annual report on Form 10-K filed
October 24, 2013. You should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Contacts: Tom Hemingway Redwood Investment Group 714-978-4425 Email
Contact Terri MacInnis Director of IR Bibicoff + MacInnis, Inc.
818-379-8500 Email
Contact Company Contact: Peter C. Wulff CFO & COO PURE
Bioscience, Inc. 619-596-8600 ext.111
Email Contact
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024